iRhythm Holdings Announces Third Quarter 2026 Financial Results
-- iRhythm Holdings, Inc. (NASDAQ: IRTC), a leading digital health care company with a mission to create trusted solutions that detect, predict, and prevent disease, today reported financial results for the three months ended September 30, 2026.
• Gross margin of 74.2%, a 310-basis point increase compared to third quarter 2025
• GAAP net loss of $29.9 million, a $24.6 million increase in net loss compared to third quarter 2025
• Adjusted EBITDA and adjusted EBITDA margin of $51.2 million and 23.1%, respectively, a $29.6 million and 1,190 - basis point improvement, respectively, compared to third quarter 2025
• Unrestricted cash, cash equivalents, and marketable securities of $560.7 million as of September 30, 2026
• Increased fiscal year 2026 revenue guidance to $890 million to $895 million and adjusted EBITDA margin guidance to 15.5% to 16.0%
• Delivered another strong quarter, driven by healthy volume-led revenue growth of Zio Monitor and robust margin expansion, with broad-based momentum across cardiology, primary care, innovative channels and international markets
• Completed the acquisition of VitalConnect on October 5, 2026, broadening our cardiac monitoring portfolio with an immediate FDA-cleared mobile cardiac telemetry offering, advancing our multi-vitals strategy, and expanding our addressable market across the continuum of care
• Published three large-scale real world studies demonstrating product superiority of Zio AT (CAMELOT-ALERT 1 ), Zio Long-Term Continuous Monitoring (EXCALIBUR 2 ), and improvements in Zio Monitor performance and diagnostic yield compared with Zio XT 3 in over 1.7 million total patients
• Submitted FDA 510(k) applications for pediatric use with our Zio Monitor long- term continuous monitoring business
• Closed a new $300 million senior secured revolving credit facility on November 3, 2026, providing additional liquidity to support our long-term growth objectives
“Our third quarter results reflect the continued strength of our core business. Demand for Zio Monitor remains robust, exceeding our expectations in the quarter, driven by volume growth across care settings and channels. We also continued to take meaningful steps forward with significant margin expansion, and consistent execution against our strategic priorities,” said Quentin Blackford, President and Chief Executive Officer of iRhythm. “With the acquisition of VitalConnect now closed, we are encouraged by the early opportunities we see to broaden our capabilities and serve more patients within the ambulatory cardiac monitoring market and across the continuum of care. With an immediate FDA-cleared mobile cardiac telemetry device, we are excited to be able to offer the marketplace a best-in-class MCT portfolio of options. We remain focused on advancing innovation, expanding access to Zio, and investing in the growth initiatives that we believe will create durable value for patients, clinicians, and stockholders.”
Revenue for the third quarter of 2026 was $221.6 million, up 14.9% from $192.9 million during the same period in 2025. The increase was driven primarily by sustained volume demand across our customer base, reflecting continued strength in our core business and contributions from newer growth channels.
Gross profit for the third quarter of 2026 was $164.5 million, up 20.0% from $137.1 million during the same period in 2025, while gross margin was 74.2%, a 310-basis point improvement compared to the third quarter of 2025. The increase in gross profit was primarily due to increased volume of Zio services, as well as a one-time benefit from tariff refunds of approximately $3.1 million. The increase in gross margin was primarily driven by continued operational efficiencies, product mix, a tariff refund one-time benefit, and disciplined execution.
Operating expenses for the third quarter of 2026 were $197.0 million, compared to $145.6 million for the same period in 2025. Adjusted operating expenses for the third quarter of 2026 were $138.6 million, compared to $141.4 million during the same period in 2025. The decrease in adjusted operating expenses, period over period, reflects a disciplined approach to investment, as we funded key growth initiatives while thoughtfully managing costs across the broader organization.
GAAP net loss for the third quarter of 2026 was $29.9 million, or net loss per diluted share of $0.90, compared with GAAP net loss of $5.2 million, or net loss per diluted share of $0.16, for the same period in 2025. Adjusted net income for the third quarter of 2026 was $27.8 million, or net income per diluted share of $0.82, compared with an adjusted net loss of $2.0 million, or net loss per diluted share of $0.06, for the same period in 2025. The improvement was primarily driven by our revenue growth and operating leverage achieved through implementation of efficiency initiatives.
Unrestricted cash, cash equivalents, and marketable securities were $560.7 million as of September 30, 2026.
For the full year 2026, iRhythm expects revenue between $890 million and $895 million, which includes approximately $16 million of expected VitalConnect revenue contribution from the October 5, 2026 acquisition close through year- end. iRhythm also expects adjusted EBITDA margin between 15.5% and 16.0%, inclusive of VitalConnect. iRhythm’s guidance reflects continued volume-led growth and operating leverage while maintaining disciplined investment in innovation and market expansion.
iRhythm’s management team will host a conference call today beginning at 1:30 p.m. PT/4:30 p.m. ET. Interested parties may access a live and archived webcast of the presentation on the “Events & Presentations” section of the company’s investor website at investors.irhythmtech.com.
iRhythm is a leading digital health care company with a mission to create trusted solutions that detect, predict, and prevent disease. Combining wearable biosensors and cloud-based data analytics with powerful proprietary algorithms, iRhythm distills data from millions of heartbeats into clinically actionable information. Through a relentless focus on patient care, iRhythm’s vision is to deliver better data, better insights, and better health for all.
We refer to certain financial measures that are not recognized under U.S. generally accepted accounting principles (GAAP) in this press release, including adjusted EBITDA, adjusted EBITDA margin, adjusted net income (loss), adjusted net income (loss) per diluted share, adjusted operating expenses and free cash flow. We use these non-GAAP financial measures for financial and operational decision-making and as a means to evaluate period-to-period comparisons. We believe that these non-GAAP financial measures may be helpful to investors. However, non-GAAP financial measures are presented for supplemental informational purposes only, have limitations as analytical tools, and should not be considered in isolation or as a substitute for financial information presented in accordance with GAAP. In addition, other companies, including companies in our industry, may calculate non-GAAP financial measures differently or may use other measures to evaluate their performance, all of which could reduce the usefulness of our disclosure of non-GAAP financial measures as a tool for comparison. See the schedules attached to this press release for additional information and reconciliations of such non-GAAP financial measures. We have not reconciled our adjusted EBITDA margin estimates for full year 2026 because certain items that impact these figures are uncertain or out of our control and cannot be reasonably predicted. Accordingly, a reconciliation of adjusted EBITDA margin estimates is not available without unreasonable effort.
Adjusted EBITDA is defined as net income (loss) before income tax provision, depreciation and amortization, interest expense, and interest income and as further adjusted for stock-based compensation expense, changes in fair value of strategic investments, impairment charges, business transformation costs, certain intellectual property litigation expenses, certain litigation settlements (net of expected insurance recoveries), costs related to the cybersecurity incident (net of expected insurance recoveries), and loss on extinguishment of debt. Business transformation costs include costs associated with professional services, employee termination and relocation, third-party merger and acquisition, integration, and other costs to augment and restructure the organization, inclusive of both outsourced and offshore resources.
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. An investor can identify these statements by the fact that they do not relate strictly to historical or current facts. They use words such as ‘anticipate’, ‘estimate’, ‘expect’, ‘intend’, ‘will’, ‘project’, ‘plan’, ‘believe’, ‘target’ and other words and terms of similar meaning in connection with any discussion of future actions or operating or financial performance. In particular, these statements include statements regarding our financial guidance, volume growth and margin expansion, market opportunity, ability to penetrate the market, expansion into new health programs, international market expansion, anticipated productivity and quality improvements, anticipated demand for our products and services and our expectations for growth, and statements regarding the anticipated benefits of the VitalConnect acquisition, including our ability to broaden our capabilities, advance our multi-vitals strategy, expand our addressable market and serve more patients across the continuum of care, our ability to create durable, long-term value for patients, clinicians and stockholders; and the anticipated benefits of our revolving credit facility. Such statements are based on current assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. These risks and uncertainties, many of which are beyond our control, include, but are not limited to: intense competition in the markets we compete in; fluctuations in our operating results; our ability to successfully integrate any acquisitions or strategic investments; risks associated with managing our growth; future U.S. and global political, competitive, reimbursement and regulatory conditions, including changing trade and tariff policies; geopolitical conflicts and tensions; distribution and supply chain disruptions and cost increases; new product and service introductions and the market acceptance of those products and services; expected pricing environment; intellectual property rights; litigation; financial market conditions; the execution and effect of our business strategy; and future business decisions made by us and our competitors. Additional risks are described in the section entitled “Risk Factors” and elsewhere in our filings made with the Securities and Exchange Commission, including our Quarterly Report on Form 10-Q expected to be filed on or about November 5, 2026. These forward- looking statements speak only as of the date of this press release and should not be unduly relied upon. iRhythm undertakes no obligation to update them except as required by law.
1. Russo P, Strom J, Nathan R, Song Y, Shokoohi M, Passman R, Reynolds M, Mittal S. Clinical and economic outcomes in diagnostic-naïve Medicare fee-for-service beneficiaries managed with alert-based ambulatory cardiac monitors: The CAMELOT- ALERT study. American Heart Journal . 2026 Aug 28. doi: 10.1016/j.ahj.2026.10759
2. Mittal S, Reynolds MR, Hughes A, Buysman EK, Hendrickson EM, Boyle K, Wright B, Ashburner JM, Turakhia M, Passman RS. Comparative Clinical Outcomes Across Ambulatory Cardiac Monitoring Modalities. Clin Cardiology. 2026 Oct;49(10):e70500. doi:10.1002/clc.70500
3. Knight BP, Pinkerton R, Ellis J, Ashburner JM, Wazni OM, Passman RS, Turakhia MP, Mittal M. Real-world performance and diagnostic yield gains of a next- generation patch-based 14-day uninterrupted ambulatory electrocardiogram monitor. Heart Rhythm O2. October 9, 2026. https://www.heartrhythmopen.com/article/S2666-5018(26)00597-0/fulltext
September 30, (unaudited) 2026 December 31, 2025 ────────────────────────────────────────────────────────────────────────────── Assets Current assets: Cash and cash $ 394,718 $ 236,012 equivalents Restricted cash 10,000 — Marketable 166,001 347,751 securities Accounts 81,126 75,706 receivable, net Inventory 23,222 21,634 Prepaid expenses and other current 55,143 21,662 assets Total current 730,210 702,765 assets Property and 176,938 151,599 equipment, net Operating lease right-of-use 37,670 41,827 assets Restricted cash 8,358 8,358 Goodwill 862 862 Long-term strategic 74,514 69,913 investments Other assets 62,889 44,718 Total assets $ 1,091,441 $ 1,020,042 Liabilities and Stockholders’ Equity Current liabilities: Accounts payable $ 15,395 $ 2,256 Accrued 167,630 128,747 liabilities Deferred revenue 4,668 4,201 Operating lease liabilities, 17,039 16,686 current portion Total current 204,732 151,890 liabilities Long-term senior 651,858 649,504 convertible notes Other noncurrent 908 908 liabilities Operating lease liabilities, 56,837 64,994 noncurrent portion Total liabilities 914,335 867,296 Stockholders’ equity: Preferred stock, $0.001 par value – 5,000 shares authorized; none — — issued and outstanding at September 30, 2026 and December 31, 2025 Common stock, $0.001 par value – 100,000 shares authorized; 33,414 shares issued and 33,185 shares 33 32 outstanding at September 30, 2026, and 32,526 shares issued and 32,297 shares outstanding at December 31, 2025 Additional 1,049,900 980,757 paid-in capital Accumulated other comprehensive -216 403 (loss) income Accumulated -847,611 -803,446 deficit Treasury stock, at cost; 229 shares at -25,000 -25,000 September 30, 2026 and December 31, 2025 Total stockholders’ 177,106 152,746 equity Total liabilities and stockholders’ $ 1,091,441 $ 1,020,042 equity
1 Net loss for the three and nine months ended September 30, 2026 includes $0.3 million and $0.9 million of acquired in-process research and development expense, and $0.3 million and $2.3 million for the three and nine months ended September 30, 2025, respectively.
2 Business transformation costs include $6.0 million associated with the VitalConnect acquisition for the three and nine months ended September 30, 2026.
3 Excludes third-party attorneys' fees and expenses associated with patent litigation brought against the Company by Welch Allyn, Inc. and Bardy Diagnostics, Inc., subsidiaries of Baxter International, Inc.
4 Excludes charges for Baxter patent litigation and securities class action litigation settlement, net of expected insurance recoveries.
5 Represents expenses directly related to the Cybersecurity Incident, net of expected insurance recoveries, including investigation and remediation, customer notifications, and professional and consultancy expenses.
7 The adjustments are for the transition from net loss per diluted share, as reported, to adjusted net income per diluted share, due to our dilutive securities, which include equity incentive awards and senior convertible notes.
8 Net cash provided by operating activities for the three and nine months ended September 30, 2026 includes $50.0 million of Baxter patent litigation settlement costs.
Full text with the tables
Exhibit 99.1
iRhythm Holdings Announces Third Quarter 2026 Financial Results
SAN FRANCISCO, November 5, 2026
-- iRhythm Holdings, Inc. (NASDAQ: IRTC), a leading digital health care company
with a mission to create trusted solutions that detect, predict, and prevent
disease, today reported financial results for the three months ended September
30, 2026.
Third Quarter 2026 Financial Highlights
• Revenue of $221.6 million, a 14.9% increase compared to third quarter 2025
• Gross margin of 74.2%, a 310-basis point increase compared to third quarter
2025
• GAAP net loss of $29.9 million, a $24.6 million increase in net loss compared
to third quarter 2025
• Adjusted EBITDA and adjusted EBITDA margin of $51.2 million and 23.1%,
respectively, a $29.6 million and 1,190 - basis point improvement, respectively,
compared to third quarter 2025
• Unrestricted cash, cash equivalents, and marketable securities of $560.7
million as of September 30, 2026
• Increased fiscal year 2026 revenue guidance to $890 million to $895 million
and adjusted EBITDA margin guidance to 15.5% to 16.0%
Recent Operational Highlights
• Delivered another strong quarter, driven by healthy volume-led revenue growth
of Zio Monitor and robust margin expansion, with broad-based momentum across
cardiology, primary care, innovative channels and international markets
• Completed the acquisition of VitalConnect on October 5, 2026, broadening our
cardiac monitoring portfolio with an immediate FDA-cleared mobile cardiac
telemetry offering, advancing our multi-vitals strategy, and expanding our
addressable market across the continuum of care
• Published three large-scale real world studies demonstrating product
superiority of Zio AT (CAMELOT-ALERT 1 ), Zio Long-Term Continuous Monitoring
(EXCALIBUR 2 ), and improvements in Zio Monitor performance and diagnostic yield
compared with Zio XT 3 in over 1.7 million total patients
• Submitted FDA 510(k) applications for pediatric use with our Zio Monitor long-
term continuous monitoring business
• Closed a new $300 million senior secured revolving credit facility on November
3, 2026, providing additional liquidity to support our long-term growth
objectives
“Our third quarter results reflect the continued strength of our core business.
Demand for Zio Monitor remains robust, exceeding our expectations in the
quarter, driven by volume growth across care settings and channels. We also
continued to take meaningful steps forward with significant margin expansion,
and consistent execution against our strategic priorities,” said Quentin
Blackford, President and Chief Executive Officer of iRhythm. “With the
acquisition of VitalConnect now closed, we are encouraged by the early
opportunities we see to broaden our capabilities and serve more patients within
the ambulatory cardiac monitoring market and across the continuum of care. With
an immediate FDA-cleared mobile cardiac telemetry device, we are excited to be
able to offer the marketplace a best-in-class MCT portfolio of options. We
remain focused on advancing innovation, expanding access to Zio, and investing
in the growth initiatives that we believe will create durable value for
patients, clinicians, and stockholders.”
Third Quarter 2026 Financial Results
Revenue for the third quarter of 2026 was $221.6 million, up 14.9% from $192.9
million during the same period in 2025. The increase was driven primarily by
sustained volume demand across our customer base, reflecting continued strength
in our core business and contributions from newer growth channels.
Gross profit for the third quarter of 2026 was $164.5 million, up 20.0% from
$137.1 million during the same period in 2025, while gross margin was 74.2%, a
310-basis point improvement compared to the third quarter of 2025. The increase
in gross profit was primarily due to increased volume of Zio services, as well
as a one-time benefit from tariff refunds of approximately $3.1 million. The
increase in gross margin was primarily driven by continued operational
efficiencies, product mix, a tariff refund one-time benefit, and disciplined
execution.
Exhibit 99.1
Operating expenses for the third quarter of 2026 were $197.0 million, compared
to $145.6 million for the same period in 2025. Adjusted operating expenses for
the third quarter of 2026 were $138.6 million, compared to $141.4 million during
the same period in 2025. The decrease in adjusted operating expenses, period
over period, reflects a disciplined approach to investment, as we funded key
growth initiatives while thoughtfully managing costs across the broader
organization.
GAAP net loss for the third quarter of 2026 was $29.9 million, or net loss per
diluted share of $0.90, compared with GAAP net loss of $5.2 million, or net loss
per diluted share of $0.16, for the same period in 2025. Adjusted net income for
the third quarter of 2026 was $27.8 million, or net income per diluted share of
$0.82, compared with an adjusted net loss of $2.0 million, or net loss per
diluted share of $0.06, for the same period in 2025. The improvement was
primarily driven by our revenue growth and operating leverage achieved through
implementation of efficiency initiatives.
Unrestricted cash, cash equivalents, and marketable securities were $560.7
million as of September 30, 2026.
2026 Annual Guidance
For the full year 2026, iRhythm expects revenue between $890 million and $895
million, which includes approximately $16 million of expected VitalConnect
revenue contribution from the October 5, 2026 acquisition close through year-
end. iRhythm also expects adjusted EBITDA margin between 15.5% and 16.0%,
inclusive of VitalConnect. iRhythm’s guidance reflects continued volume-led
growth and operating leverage while maintaining disciplined investment in
innovation and market expansion.
Webcast and Conference Call Information
iRhythm’s management team will host a conference call today beginning at 1:30
p.m. PT/4:30 p.m. ET. Interested parties may access a live and archived webcast
of the presentation on the “Events & Presentations” section of the company’s
investor website at investors.irhythmtech.com.
About iRhythm Holdings, Inc.
iRhythm is a leading digital health care company with a mission to create
trusted solutions that detect, predict, and prevent disease. Combining wearable
biosensors and cloud-based data analytics with powerful proprietary algorithms,
iRhythm distills data from millions of heartbeats into clinically actionable
information. Through a relentless focus on patient care, iRhythm’s vision is to
deliver better data, better insights, and better health for all.
Use of Non-GAAP Financial Measures
We refer to certain financial measures that are not recognized under U.S.
generally accepted accounting principles (GAAP) in this press release, including
adjusted EBITDA, adjusted EBITDA margin, adjusted net income (loss), adjusted
net income (loss) per diluted share, adjusted operating expenses and free cash
flow. We use these non-GAAP financial measures for financial and operational
decision-making and as a means to evaluate period-to-period comparisons. We
believe that these non-GAAP financial measures may be helpful to investors.
However, non-GAAP financial measures are presented for supplemental
informational purposes only, have limitations as analytical tools, and should
not be considered in isolation or as a substitute for financial information
presented in accordance with GAAP. In addition, other companies, including
companies in our industry, may calculate non-GAAP financial measures differently
or may use other measures to evaluate their performance, all of which could
reduce the usefulness of our disclosure of non-GAAP financial measures as a tool
for comparison. See the schedules attached to this press release for additional
information and reconciliations of such non-GAAP financial measures. We have not
reconciled our adjusted EBITDA margin estimates for full year 2026 because
certain items that impact these figures are uncertain or out of our control and
cannot be reasonably predicted. Accordingly, a reconciliation of adjusted EBITDA
margin estimates is not available without unreasonable effort.
Adjusted EBITDA is defined as net income (loss) before income tax provision,
depreciation and amortization, interest expense, and interest income and as
further adjusted for stock-based compensation expense, changes in fair value of
strategic investments, impairment charges, business transformation costs,
certain intellectual property litigation expenses, certain litigation
settlements (net of expected insurance recoveries), costs related to the
cybersecurity incident (net of expected insurance recoveries), and loss on
extinguishment of debt. Business transformation costs include costs associated
with professional services, employee termination and relocation, third-party
merger and acquisition, integration, and other costs to augment and restructure
the organization, inclusive of both outsourced and offshore resources.
Exhibit 99.1
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of
Section 27A of the Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended, and the Private Securities
Litigation Reform Act of 1995. An investor can identify these statements by the
fact that they do not relate strictly to historical or current facts. They use
words such as ‘anticipate’, ‘estimate’, ‘expect’, ‘intend’, ‘will’, ‘project’,
‘plan’, ‘believe’, ‘target’ and other words and terms of similar meaning in
connection with any discussion of future actions or operating or financial
performance. In particular, these statements include statements regarding our
financial guidance, volume growth and margin expansion, market opportunity,
ability to penetrate the market, expansion into new health programs,
international market expansion, anticipated productivity and quality
improvements, anticipated demand for our products and services and our
expectations for growth, and statements regarding the anticipated benefits of
the VitalConnect acquisition, including our ability to broaden our capabilities,
advance our multi-vitals strategy, expand our addressable market and serve more
patients across the continuum of care, our ability to create durable, long-term
value for patients, clinicians and stockholders; and the anticipated benefits of
our revolving credit facility. Such statements are based on current assumptions
that involve risks and uncertainties that could cause actual outcomes and
results to differ materially. These risks and uncertainties, many of which are
beyond our control, include, but are not limited to: intense competition in the
markets we compete in; fluctuations in our operating results; our ability to
successfully integrate any acquisitions or strategic investments; risks
associated with managing our growth; future U.S. and global political,
competitive, reimbursement and regulatory conditions, including changing trade
and tariff policies; geopolitical conflicts and tensions; distribution and
supply chain disruptions and cost increases; new product and service
introductions and the market acceptance of those products and services; expected
pricing environment; intellectual property rights; litigation; financial market
conditions; the execution and effect of our business strategy; and future
business decisions made by us and our competitors. Additional risks are
described in the section entitled “Risk Factors” and elsewhere in our filings
made with the Securities and Exchange Commission, including our Quarterly Report
on Form 10-Q expected to be filed on or about November 5, 2026. These forward-
looking statements speak only as of the date of this press release and should
not be unduly relied upon. iRhythm undertakes no obligation to update them
except as required by law.
Investor Contact
Francis Pruell
[email protected]
Media Contact
Kassandra Perry
[email protected]
1. Russo P, Strom J, Nathan R, Song Y, Shokoohi M, Passman R, Reynolds M, Mittal
S. Clinical and economic outcomes in diagnostic-naïve Medicare fee-for-service
beneficiaries managed with alert-based ambulatory cardiac monitors: The CAMELOT-
ALERT study. American Heart Journal . 2026 Aug 28. doi: 10.1016/j.ahj.2026.10759
2. Mittal S, Reynolds MR, Hughes A, Buysman EK, Hendrickson EM, Boyle K, Wright
B, Ashburner JM, Turakhia M, Passman RS. Comparative Clinical Outcomes Across
Ambulatory Cardiac Monitoring Modalities. Clin Cardiology. 2026
Oct;49(10):e70500. doi:10.1002/clc.70500
3. Knight BP, Pinkerton R, Ellis J, Ashburner JM, Wazni OM, Passman RS, Turakhia
MP, Mittal M. Real-world performance and diagnostic yield gains of a next-
generation patch-based 14-day uninterrupted ambulatory electrocardiogram
monitor. Heart Rhythm O2. October 9, 2026.
https://www.heartrhythmopen.com/article/S2666-5018(26)00597-0/fulltext
Exhibit 99.1
IRHYTHM HOLDINGS, INC.
Condensed Consolidated Balance Sheets
(in thousands, except par value)
September 30,
(unaudited) 2026 December 31, 2025
──────────────────────────────────────────────────────────────────────────────
Assets
Current assets:
Cash and cash $ 394,718 $ 236,012
equivalents
Restricted cash 10,000 —
Marketable 166,001 347,751
securities
Accounts 81,126 75,706
receivable, net
Inventory 23,222 21,634
Prepaid expenses
and other current 55,143 21,662
assets
Total current 730,210 702,765
assets
Property and 176,938 151,599
equipment, net
Operating lease
right-of-use 37,670 41,827
assets
Restricted cash 8,358 8,358
Goodwill 862 862
Long-term
strategic 74,514 69,913
investments
Other assets 62,889 44,718
Total assets $ 1,091,441 $ 1,020,042
Liabilities and
Stockholders’
Equity
Current
liabilities:
Accounts payable $ 15,395 $ 2,256
Accrued 167,630 128,747
liabilities
Deferred revenue 4,668 4,201
Operating lease
liabilities, 17,039 16,686
current
portion
Total current 204,732 151,890
liabilities
Long-term senior 651,858 649,504
convertible notes
Other noncurrent 908 908
liabilities
Operating lease
liabilities, 56,837 64,994
noncurrent
portion
Total liabilities 914,335 867,296
Stockholders’
equity:
Preferred stock,
$0.001 par value
–
5,000 shares
authorized; none — —
issued and
outstanding at
September 30,
2026 and
December 31, 2025
Common stock,
$0.001 par value
– 100,000
shares
authorized;
33,414 shares
issued
and 33,185 shares 33 32
outstanding at
September 30,
2026, and 32,526
shares
issued and 32,297
shares
outstanding at
December 31, 2025
Additional 1,049,900 980,757
paid-in capital
Accumulated other
comprehensive -216 403
(loss)
income
Accumulated -847,611 -803,446
deficit
Treasury stock,
at cost; 229
shares at -25,000 -25,000
September 30,
2026 and December
31, 2025
Total
stockholders’ 177,106 152,746
equity
Total liabilities
and stockholders’ $ 1,091,441 $ 1,020,042
equity
Exhibit 99.1
IRHYTHM HOLDINGS, INC.
Condensed Consolidated Statements of Operations
(in thousands, except per share data)
Three Nine
Months Months
Ended Ended
Septem… Septemb…
(unaud… 2026 30, 2025 2026 30, 2025
──────────────────────────────────────────────────────────────────────────────
Revenu… $ 221,592 $ 192,884 $ 645,154 $ 538,248
net
Cost of 57,098 55,762 176,102 159,053
revenue
Gross 164,494 137,122 469,052 379,195
profit
Operat…
expens…
Resear…
and 20,599 21,033 61,800 63,564
develo…
Acquir…
in-pro…
resear… 303 302 898 2,296
and
develo…
Sellin…
general 125,636 124,216 393,175 370,549
and
admini…
Litiga… 49,788 — 63,738 —
settle…
Impair… 723 — 723 2,479
charges
Total
operat… 197,049 145,551 520,334 438,888
expens…
Loss
from -32,555 -8,429 -51,282 -59,693
operat…
Intere…
and
other
income,
net:
Intere… 4,699 5,944 14,354 16,184
income
Intere… -3,298 -3,281 -9,882 -9,832
expense
Other
income, 1,303 578 3,145 3,717
net
Total
intere…
and 2,704 3,241 7,617 10,069
other
income,
net
Loss
before -29,851 -5,188 -43,665 -49,624
income
taxes
Income
tax — 24 500 506
provis…
Net $ -29,851 $ -5,212 $ -44,165 $ -50,130
loss
Net
loss
per
common $ -0.90 $ -0.16 $ -1.35 $ -1.57
share,
basic
and
diluted
Weight…
shares,
basic 33,099 32,170 32,836 31,919
and
diluted
Exhibit 99.1
IRHYTHM HOLDINGS, INC.
Reconciliation of GAAP to Non-GAAP Financial Information
(in thousands, except per share data)
Three Nine
Months Months
(unau… Ended Ended
Adjus… Septe… Septe…
EBITDA 30, 30,
recon… 2026 2025 2026 2025
──────────────────────────────────────────────────────────────────────────────
Net
loss, $ -29,851 $ -5,212 $ -44,165 $ -50,1…
as
repor…
Inter… 3,298 3,281 9,882 9,832
expen…
Inter… -4,699 -5,944 -14,354 -16,1…
income
Chang…
in
fair
value -832 -894 -3,101 -3,889
of
strat…
inves…
Income
tax — 24 500 506
provi…
Depre…
and 5,324 5,173 15,588 15,488
amort…
Stock… 19,490 21,006 61,020 67,177
compe…
Impai… 723 — 723 2,479
charg…
Busin…
trans… 6,590 913 8,094 2,341
costs2
Intel…
prope… 1,211 3,212 9,828 7,000
litig…
expen…
Litig… 49,788 — 63,738 —
settl…
Cyber… 142 — 828 —
incid…
Adjus… $ 51,184 $ 21,559 $ 108,581 $ 34,620
EBITDA
Adjus…
net
income
(loss)
recon…
Net
loss, $ -29,851 $ -5,212 $ -44,165 $ -50,1…
as
repor…
Impai… 723 — 723 2,479
charg…
Busin…
trans… 6,590 913 8,094 2,341
costs2
Intel…
prope… 1,211 3,212 9,828 7,000
litig…
expen…
Chang…
in
fair
value -832 -894 -3,101 -3,889
of
strat…
inves…
Litig… 49,788 — 63,738 —
settl…
Cyber… 142 — 828 —
incid…
Tax
effect 44 5 -153 -300
of
adjus…
Adjus…
net $ 27,815 $ -1,976 $ 35,792 $ -42,4…
income
(loss)
Inter…
expen…
on
senior $ 3,298 $ — $ — $ —
conve…
notes,
net of
tax
Numer…
used
in
compu…
adjus…
net $ 31,113 $ -1,976 $ 35,792 $ -42,4…
income
(loss)
per
dilut…
share
Exhibit 99.1
IRHYTHM HOLDINGS, INC.
Reconciliation of GAAP to Non-GAAP Financial Information (continued)
(in thousands, except per share data)
(una…
Adju…
net
inco… Three Nine
(los… Months Months
per Ended Ended
dilu… Septem… Septe…
share 30, 30,
reco… 2026 2025 2026 2025
──────────────────────────────────────────────────────────────────────────────
Net
loss, $ -0.90 $ -0.16 $ -1.35 $ -1.57
as
repo…
Impa… 0.02 — 0.02 0.08
char…
Busi…
tran… 0.17 0.03 0.24 0.07
cost…
Inte…
prop… 0.03 0.10 0.29 0.22
liti…
expe…
Chan…
in
fair
value -0.02 -0.03 -0.09 -0.12
of
stra…
inve…
Liti… 1.31 — 1.90 —
sett…
Cybe… — — 0.02 —
inci…
Tax
effe… — — — -0.01
of
adju…
Inte…
expe…
on
seni…
conv… 0.09 — — —
note…
net
of
tax
Impa…
of
adju…
to 0.12 — 0.04 —
dilu…
shar…
as
repo…
Adju…
net
inco…
(los… $ 0.82 $ -0.06 $ 1.07 $ -1.33
per
dilu…
share
Weig…
shar…
basic
and 33,099 32,170 32,836 31,919
dilu…
as
repo…
Equi…
ince… 337 — 634 —
awar…
Seni…
conv… 4,492 — — —
notes
Weig…
shar…
used
in
comp…
adju… 37,928 32,170 33,470 31,919
net
inco…
(los…
per
dilu…
share
Adju…
oper…
expe…
reco…
Oper…
expe… $ 197,0… $ 145,551 $ 520,334 $ 438,8…
as
repo…
Impa… -723 — -723 -2,479
char…
Busi…
tran… -6,590 -913 -8,094 -2,341
cost…
Inte…
prop… -1,211 -3,212 -9,828 -7,000
liti…
expe…
Liti… -49,7… — -63,738 —
sett…
Cybe… -142 — -828 —
inci…
Adju…
oper… $ 138,5… $ 141,426 $ 437,123 $ 427,0…
expe…
Free
cash
flow
reco…
Net
cash
prov… $ 4,438 $ 34,883 $ 29,345 $ 54,651
by
oper…
acti…
Less:
Purc…
of -15,9… -14,831 -36,453 -34,6…
prop…
and
equi…
Free
cash $ -11,5… $ 20,052 $ -7,108 $ 20,032
flow
*Certain numbers expressed may not sum due to rounding.
1 Net loss for the three and nine months ended September 30, 2026 includes $0.3
million and $0.9 million of acquired in-process research and development
expense, and $0.3 million and $2.3 million for the three and nine months ended
September 30, 2025, respectively.
2 Business transformation costs include $6.0 million associated with the
VitalConnect acquisition for the three and nine months ended September 30, 2026.
3 Excludes third-party attorneys' fees and expenses associated with patent
litigation brought against the Company by Welch Allyn, Inc. and Bardy
Diagnostics, Inc., subsidiaries of Baxter International, Inc.
4 Excludes charges for Baxter patent litigation and securities class action
litigation settlement, net of expected insurance recoveries.
5 Represents expenses directly related to the Cybersecurity Incident, net of
expected insurance recoveries, including investigation and remediation, customer
notifications, and professional and consultancy expenses.
6 Income tax impact of Non-GAAP adjustments listed.
7 The adjustments are for the transition from net loss per diluted share, as
reported, to adjusted net income per diluted share, due to our dilutive
securities, which include equity incentive awards and senior convertible notes.
8 Net cash provided by operating activities for the three and nine months ended
September 30, 2026 includes $50.0 million of Baxter patent litigation settlement
costs.